A Phase 1/2, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of JIN-A02 in Patients With EGFR Mutant Advanced Non-small Cell Lung Cancer
Latest Information Update: 05 Jun 2025
At a glance
- Drugs JIN-A02 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; First in man
- Sponsors J Ints Bio
Most Recent Events
- 01 Jun 2025 According to a J INTS BIO media release, company presented interim results from the global Phase 1/2 clinical trial of JIN-A02 at the American Society of Clinical Oncology 2025 (ASCO 2025), the world's largest oncology conference, held in Chicago, USA.
- 16 May 2025 Planned End Date changed from 30 Nov 2025 to 30 Sep 2026.
- 16 May 2025 Planned primary completion date changed from 31 Jul 2024 to 30 Sep 2026.